Skip to main content
. 2017 Jul 10;12(7):e0180949. doi: 10.1371/journal.pone.0180949

Table 1. Clinical and biochemical characteristics of individuals with T2DM stratified by presence of DR (n = 435).

Variables DR (172) Non-DR (263) All (435) P-value
Entry age (yrs) 55.3 ± 9.3 50.8 ± 12.8 52.6 ± 11.8 <0.001
Age group, No., (%)
21–29 0 (0) 21 (8.0) 21 (4.8)
30–39 12 (7.0) 30 (11.4) 42 (9.7)
40–49 25 (14.5) 51 (20.5) 79 (18.2)
50–59 85 (49.4) 85 (32.2) 170 (39.1)
60–69 39 (22.7) 64 (24.3) 103(23.7)
>70 11 (6.4) 9 (3.4) 20 (4.6) <0.001
Male gender, No., (%) 58.1 60.5 59.5 0.232
Ethnicity, No., (%)
Chinese 76 (45.2) 154 (60.9) 230 (54.6)  
Malays 48 (28.6) 36 (14.2) 84 (20.0)  
Indians 44 (26.2) 63 (24.9) 107 (25.4) 0.001
BMI (kg/m2) 28.3 ± 5.8 28.3 ± 5.7 28.3 ± 5.7 0.901
Smoking (current and former), No., (%) 29 (26.9) 21 (8.0) 50 (11.5) 0.005
T2DM burden
Duration (yrs) 14.5±9.2 9.3±8.3 11.3±9.0 <0.001
HbA1c (%) 8.4±1.4 7.9±1.5 8.1±1.4 0.009
Oral glycemic medication,a No., (%) 157 (91.8) 240 (91.6) 397 (91.7) 0.938
Insulin, No., (%) 89 (52.5) 83 (31.7) 172 (39.7) <0.001
RAS medication,b No., (%) 129 (75.0) 150 (57.5) 279 (64.4) <0.001
History of CVD
IHD,c No., (%) 23 (13.8) 30 (11.4) 53 (12.5) 0.602
Stroke No., (%) 15 (8.8) 8 (3.0) 23 (5.6) 0.057
CKD,d No., (%) 135 (78.5) 103 (39.2) 238 (54.7) <0.001
Neuropathy,e No., (%) 46 (27.5) 10 (4.0) 56 (13.5) <0.001

aUsage of insulin secretagogues, Rosi-/Pio-glitazone or metformin

bRenin-angiotensin system (RAS) medication, angiotensin-converting-enzyme or angiotensin receptor blockers

cIschemic heart disease (IHD), blockade of arteries to the heart, heart Attack, balloon angioplasty of blocked artery of the heart, or heart bypass operation

dCKD, eGFR <60 ml/min/1.73m2 AND/OR ACR≥30mg/g

eNeurothesiometer reading>25 V or monofilament sensory test result below 8 out of 10 points on either side of the feet.

HbA1C, hemoglobin A1c; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; CVD, cardiovascular disease; CKD, chronic kidney disease